Search Bar & Filters
Found 47 Actively Recruiting clinical trials
Actively Recruiting
Diabetes is the leading cause of kidney failure in the UK, and managing diabetes in people with advanced kidney disease is especially challenging due to fluctuating glucose levels and higher risk of unsafe low glucose readings. This trial investigates whether automated insulin delivery AID systems can improve glucose control and quality of life for people with type 2 diabetes who are treated with multiple insulin injections and undergoing regular haemodialysis. The study is conducted across four UK centers with a parallel design involving about 84 participants. Participants will wear a glucose sensor at the start and will be randomly assigned to one of two groups one group will use the Omnipod 5 automated insulin delivery system, while the other will continue with usual care augmented by continuous glucose monitoring. Each treatment stage lasts 12 weeks, with the entire study lasting about 18 weeks per participant. Researchers will compare glucose levels between the two groups and collect feedback through questionnaires and interviews. During the study, participants will be closely monitored for safety and their glucose levels will be tracked using continuous sensors. Various questionnaires will assess treatment satisfaction, quality of life, and diabetes-related distress. The main outcome measured is the time glucose levels remain in the target range between 3.9 and 10 mmolL over 12 weeks. Secondary measures include time spent below target glucose levels, episodes of severe hypoglycemia, ketosis events, and several quality of life assessments. This comprehensive monitoring aims to understand the impact of automated insulin delivery in this population.
Actively Recruiting
Researchers are studying patients with cirrhosis caused by alcohol-related or metabolic dysfunction-associated steatotic liver disease MASLD. The trial aims to evaluate whether taking capsules containing faecal microbiota from healthy donors can reduce infections and mortality in these patients. This Phase 3 trial follows earlier research that showed faecal microbiota transplantation FMT delivered via endoscopy was safe and feasible, leading to the development of capsules for easier treatment administration. Participants will be randomly assigned to receive either encapsulated FMT or placebo capsules that look identical but contain no active treatment. They will take five capsules every three months over a total period of 21 months or until they develop an infection requiring hospital admission. This double-blind trial means neither participants nor study staff will know which treatment is given. The study will last up to 24 months including follow-up, monitoring effects on infection rates, liver health, immune system function, and antibiotic resistance. Throughout the trial, participants will be regularly assessed for infections, liver disease progression, hospital admissions, quality of life, mental health, alcohol use, and safety of FMT treatment. Laboratory tests will examine immune response and bacterial resistance. The primary outcome is the time until first infection needing hospital care. The study involves detailed monitoring and follow-up visits for up to two years to understand the treatments impact and safety in patients with cirrhosis.
Actively Recruiting
Researchers are evaluating whether less frequent dosing of pembrolizumab after six months of standard treatment is safe and effective for patients with advanced non-small cell lung cancer NSCLC. Pembrolizumab, an immunotherapy targeting the PD-1 receptor, has improved outcomes in NSCLC, but current dosing every six weeks for up to two years may result in overtreatment. This UK phase III trial aims to find if reducing dose frequency can maintain effectiveness while improving quality of life and lowering costs. Participants who have received six months of pembrolizumab, with or without chemotherapy, and plan to continue treatment will be randomized to receive pembrolizumab intravenously every six weeks control or every twelve weeks initially. If the 12-week dosing is found to be not less effective, additional groups receiving doses every nine, fifteen, and eighteen weeks will be included. Patients who experience disease progression while on reduced frequency dosing can return to the standard six-week schedule. Throughout the study, participants will be monitored for overall survival at 18 months from randomization, along with other outcomes such as progression-free survival, response rate, duration of response, and adverse events over two years. The study involves regular hospital visits for treatment and assessments, and the results may lead to safer, more convenient treatment options for NSCLC patients. The total participation time varies depending on individual treatment and follow-up schedules.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.
Actively Recruiting
Researchers are evaluating the investigational drug PF-06821497 mevrometostat combined with enzalutamide compared to enzalutamide alone in men with metastatic castration-resistant prostate cancer mCRPC who have not previously received certain systemic treatments. This global, multicenter, randomized Phase 3 study focuses on participants who have mCRPC but have only received androgen deprivation therapy or first-generation anti-androgen agents, excluding prior treatment with androgen receptor signaling inhibitors such as enzalutamide or abiraterone. Participants are randomly assigned to one of two groups one receiving PF-06821497 twice daily plus enzalutamide once daily, and the other receiving a placebo twice daily plus enzalutamide once daily. The study includes several phases screening, randomization, treatment, safety follow-up, and long-term follow-up. Treatment is continuous oral dosing during the treatment phase. Throughout the study, participants will undergo regular assessments including scans, laboratory tests, and patient-reported questionnaires to measure outcomes such as radiographic progression-free survival, overall survival, pain progression, prostate specific antigen levels, and quality of life. Safety is monitored continuously, and follow-up can last up to approximately five years after randomization to evaluate long-term effects and treatment impact.
Actively Recruiting
Researchers are evaluating two types of stereotactic body radiotherapy SBRT in men with high risk localized prostate cancer, where the cancer is confined to the prostate but may grow quickly or spread. The study aims to compare the safety and effectiveness of delivering radiotherapy to the prostate alone versus the prostate plus surrounding lymph nodes, with both treatments given in only 5 sessions. This phase III trial is designed to see if including lymph nodes reduces the chance of cancer returning and to review any side effects that occur. Participants will be randomly assigned to one of two groups. One group will receive SBRT targeting the prostate and seminal vesicles, delivering 36.25Gy in 5 fractions on alternate days with 40Gy to the prostate clinical target volume. The other group will get the same prostate treatment plus 25Gy in 5 fractions to the pelvic lymph nodes on alternate days. Treatments will be provided over approximately two weeks at experienced NHS radiotherapy centers that meet quality standards for these therapies. During the study, participants will be monitored for at least three and a half years to assess time to biochemical or clinical failure, which is the main outcome. Researchers will also track acute and late side effects, cancer relapse, survival rates, patient-reported outcomes, and adherence to treatment protocols for up to five years post-randomization. Regular imaging and assessments will be performed before treatment to confirm eligibility and exclude metastatic disease. Overall, participants can expect close monitoring and follow-up throughout and after their treatment period.
Actively Recruiting
Researchers are evaluating the antidepressant effects of ALTO-100 compared to a placebo in adults with Bipolar Disorder I or II who are currently experiencing a major depressive episode. This study aims to understand how patient characteristics may influence treatment outcomes when ALTO-100 is used along with a mood stabilizer andor an atypical antipsychotic. The trial also focuses on assessing safety, tolerability, and efficacy during a later open-label treatment phase. Participants in the study will be randomly assigned to receive either ALTO-100 at a dose of 40 mg twice daily or a matching placebo for 6 weeks during the double-blind treatment period. Those who qualify and continue will enter an open-label period lasting up to 7 weeks, where all will receive ALTO-100 40 mg twice daily. The study uses a quadruple-blind design to ensure unbiased results. During the trial, participants will undergo regular assessments of depression symptoms using scales such as the Montgomery-sberg Depression Rating Scale MADRS, Patient Health Questionnaire PHQ-9, and Clinician Global Impression Scale-severity CGI-S. Safety monitoring includes tracking adverse events, heart rate, blood pressure, weight, and suicidality over a total period of up to 13 weeks. The study evaluates changes from baseline to week 6 during the double-blind phase and continues safety assessments through the open-label period.
Actively Recruiting
Healthy Volunteer
Sarcopenia is the loss of skeletal muscle mass and function often seen in older adults, which can impact physical independence and metabolic health. Researchers are studying how different doses of a new leucine-enriched whey protein supplement, called super-whey, affect muscle building in older adults. This study aims to find the best dose to stimulate muscle protein synthesis, especially since muscle loss is linked to reduced response to protein and exercise in aging. Participants will receive three different low doses of the super-whey protein supplement 5 grams, 10 grams, and 20 grams. These doses will be given as single bolus servings in a randomized crossover manner, meaning each participant will try all doses in a random order. The doses are considered safe and similar to normal protein intake recommendations. The study will measure muscle protein synthesis both at rest and after acute exercise in older adults. During the study, participants will be monitored for muscle protein fractional synthetic rates at 3 and 6 hours after supplement intake. Blood samples will be taken over 7.5 hours to measure amino acid levels. Participants must be physically able to perform resistance exercise and will be assessed under close supervision by the research team. The study will help understand how different protein doses affect muscle building in older adults and will last until October 2026.
Actively Recruiting
Healthy Volunteer
Skeletal muscle, making up about 45-55% of body mass, is vital for movement, support, and overall metabolism. As people age, they often experience sarcopenia, which is the loss of muscle mass and function. This condition increases risks like disability, falls, and death. One key factor in sarcopenia is anabolic resistance, where older muscles respond less effectively to nutrition and exercise, especially in terms of muscle protein synthesis MPS. This study aims to explore whether enhancing protein with leucine, an amino acid important for stimulating MPS, can improve muscle health in older adults. Researchers are comparing two types of protein supplements a super-whey SW protein enriched with approximately 40% more leucine and 20% more essential amino acids, against a standard isonitrogenous whey protein WP. Participants will receive 20g of their assigned supplement with controlled meals during study visits. The study will evaluate the effects of these supplements both in a rested state and within 24 hours following exercise, under controlled diet and activity conditions. Participants will undergo a three-day lead-in period with a controlled diet and limited physical activity, followed by two and a half days of study visits. During these visits, researchers will closely monitor muscle protein synthesis responses. The primary measurement is muscle protein synthesis, assessed in both rested and post-exercise states. This trial is randomized and triple-blinded, focusing on healthy male volunteers aged 65 and older, with careful monitoring throughout the study period.
1-10 of 47
1